Multiplexed Transcriptomics for Screening Drug Combinations and Defining the Mechanism of Action of HCC Therapeutics at Single‐Cell Resolution
Cell Proliferation · 2026
DOI: 10.1111/cpr.70148 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Proliferation, 2026. Verfasst von Mengmeng Jiang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Liangzhu Laboratory, Zhejiang University, Hangzhou, China. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Single-Cell Analysis, Transcriptome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Zhejiang Provincial Natural Science Foundation of China, The National Natural Science Foundation of China.
Abstract (Originalsprache)
Compared to classical drug screening, single‐cell screening not only significantly enhances throughput but also provides richer transcriptional response information. In this study, we employed the high‐throughput and high‐sensitive single‐nucleus sequencing platform, snHH‐seq, to screen clinical drug combinations with anti‐hepatocellular carcinoma (HCC) activity. Single‐cell transcriptomics analysis revealed that the HY combination (HHT and YM155) exhibited the strongest suppression of tumour cell proliferation, a finding validated by both in vitro and in vivo functional assays. Further investigation suggested that HY triggers ferroptosis, as evidenced by rescue from cell death upon co‐treatment with the ferroptosis inhibitor Fer‐1. Subcluster analysis identified distinct tumour cell subclusters' responses to HY treatment. A gene regulatory network analysis highlighted JUN as a key regulator mediating proliferation inhibition, primarily active in the apoptotic cell subcluster. These findings illustrate how integrating high‐throughput screening with mechanistic dissection can accelerate the discovery of targeted drug combination therapies, and offer a blueprint for precise interventions using pathway vulnerabilities and cellular heterogeneity in HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Liangzhu Laboratory, Zhejiang University, Hangzhou, China.
- Bone Marrow Transplantation Center of the First Affiliated Hospital, and Center for Stem Cell and Regenerative Medicine, Zhejiang University School of Medicine, Hangzhou, China.
- Institute of Hematology, Zhejiang University, Hangzhou, China.
- First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
ORCID-Profile: Mengmeng Jiang, Haide Chen, Guoxia Wen, Yuqing Mei, Wenzhao Zhou, Bin Xu, Tingyue Zhang, Guangyan Li, Junqing Wu, Xiaoping Han, Xudong Fu, Guoji Guo, Jingjing Wang
Förderung
- Zhejiang Provincial Natural Science Foundation of China
- The National Natural Science Foundation of China
Zitieren
APA
Jiang, M., Chen, H., Wen, G., Mei, Y., Zhou, W., Xu, B., Zhang, T., Li, G., Wu, J., Han, X., Fu, X., Guo, G., & Wang, J. (2026). Multiplexed Transcriptomics for Screening Drug Combinations and Defining the Mechanism of Action of HCC Therapeutics at Single‐Cell Resolution. Cell Proliferation. https://doi.org/10.1111/cpr.70148
Vancouver
Jiang M, Chen H, Wen G, Mei Y, Zhou W, Xu B, et al. Multiplexed Transcriptomics for Screening Drug Combinations and Defining the Mechanism of Action of HCC Therapeutics at Single‐Cell Resolution. Cell Proliferation. 2026. doi:10.1111/cpr.70148
BibTeX
@article{Jiang2026,
author = {Jiang, Mengmeng and Chen, Haide and Wen, Guoxia and Mei, Yuqing and Zhou, Wenzhao and Xu, Bin and Zhang, Tingyue and Li, Guangyan and Wu, Junqing and Han, Xiaoping and Fu, Xudong and Guo, Guoji and Wang, Jingjing},
title = {Multiplexed Transcriptomics for Screening Drug Combinations and Defining the Mechanism of Action of HCC Therapeutics at Single‐Cell Resolution},
journal = {Cell Proliferation},
year = {2026},
doi = {10.1111/cpr.70148}
}
EUVIMED